Endoscopic Full Thickness Resection for Gastric GIST
Launched by CHINESE UNIVERSITY OF HONG KONG · Dec 12, 2019
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to treat gastric GIST, which are tumors found in the stomach. The researchers want to see if a procedure called endoscopic full thickness resection is effective and safe for removing these tumors. This method involves using an endoscope, a thin tube with a camera, to safely remove the tumor from the stomach lining.
To participate in the trial, you must be between 18 and 80 years old and have a specific type of stomach tumor that is between 10mm and 30mm in size. Unfortunately, if you are pregnant, have certain health issues that make anesthesia risky, or have tumors in other stomach locations, you may not be eligible. If you join the trial, you can expect to undergo this minimally invasive procedure, and the team will carefully monitor your recovery and health outcomes to gather valuable information about this treatment option.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \> 18 and ≤ 80
- • 2. Gastric submucosal tumors located at cardia, lesser curvature and antrum
- • 3. Size of the submucosal tumor between 10mm to 30mm as assessed by endoscopic
- Exclusion Criteria:
- • 1. Patients who are considered as unfit for general anesthesia
- • 2. ASA class ≥ IV or moribund patients
- • 3. Pregnancy
- • 4. Gastric submucosal tumors located at greater curvature and fundus
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Outside Of Us & Canada, China
Hong Kong, , China
Patients applied
Trial Officials
Philip Wai Yan Chiu, MD, FRCSEd
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials